Global Healthcare Analyst

Tina Banerjee

Thematic (Sector/Industry)

<ul>
<li>Hansoh’s risvutatug rezetecan for second-line treatment of SCLC has been included in NMPA’s Priority Review. InSilico completed first patient enrollment and dosing in Phase 3 trial evaluating rentosertib in IPF.</li>
<li>Shionogi received approval in Australia for cefiderocol for the treatment of carbapenem-resistant Gram-negative bacterial infections. Kyowa Kirin’s Phase 2 trial for ophthalmic drug candidate did not meet primary endpoint.</li>
<li>Samsung Biologics signed a new CMO contract worth $262M with a European pharmaceutical company. SK Biopharmaceutical received notification regarding FDA's partial clinical hold on its epilepsy drug candidate, opakalim.</li>
</ul>


Hansoh’s risvutatug rezetecan for second-line treatment of SCLC has been included in NMPA’s Priority Review. InSilico completed first patient enrollment and dosing in Phase 3 trial evaluating rentosertib in IPF.
Shionogi received approval in Australia for cefiderocol for the treatment of carbapenem-resistant Gram-negative bacterial infections. Kyowa Kirin’s Phase 2 trial for ophthalmic drug candidate did not meet primary endpoint.
Samsung Biologics signed a new CMO contract worth $262M with a European pharmaceutical company. SK Biopharmaceutical received notification regarding FDA's partial clinical hold on its epilepsy drug candidate, opakalim.


APAC Healthcare Weekly (Sept 13) – Hansoh, InSilico, Shionogi, Kyowa Kirin, Samsung Bio, SK Biopharm

Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

Shenton Research

Shenton Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Quantitative Analysis

<ul>
<li>We analyzed the changes in short interest of Bursa stocks as of Oct 9th. The aggregated short interest is USD1,390m.</li>
<li>We tabulate league tables for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.</li>
<li>We highlight short interest changes in CIMB, Press Metal, Gamuda, AMMB, Pentamaster.</li>
</ul>


We analyzed the changes in short interest of Bursa stocks as of Oct 9th. The aggregated short interest is USD1,390m.
We tabulate league tables for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.
We highlight short interest changes in CIMB, Press Metal, Gamuda, AMMB, Pentamaster.


Bursa Short Interest Weekly (Oct 9th): CIMB, Press Metal, Gamuda, AMMB, Pentamaster

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/top-glove-corp-bhd" target="_blank" data-smartkarma-citation="entities:20759:1" rel="noopener">Top Glove Corp (TOPG MK)</a> revenue grew 39% YoY to RM 3.5B in FY25 on the back of sales volume increasing 55%, because of competitive pricing.</li>
<li>Drop in raw material costs resulted in FY25 EBITDA rising 79% YoY to RM 454M. The FY25 Core EBITDA margin of 13%, was a significant improvement from 10% in FY24.</li>
<li>With the company’s rigorous cost control, competitive pricing efforts in fray and resulting in volumes strengthening, we prefer to be positive on the stock.</li>
</ul>



Top Glove Corp (TOPG MK) revenue grew 39% YoY to RM 3.5B in FY25 on the back of sales volume increasing 55%, because of competitive pricing.
Drop in raw material costs resulted in FY25 EBITDA rising 79% YoY to RM 454M. The FY25 Core EBITDA margin of 13%, was a significant improvement from 10% in FY24.
With the company’s rigorous cost control, competitive pricing efforts in fray and resulting in volumes strengthening, we prefer to be positive on the stock.


Top Glove Corp (TOPG MK): Competitive Pricing Alongside Cost Control Drive Sales and Margins

<ul>
<li>Last week, the U.S. DoD designated Wuxi AppTec as a “Chinese military company.” In response, Wuxi AppTec has filed a complaint at the U.S. District Court.</li>
<li>CSPC Pharmaceutical received trial approval for semaglutide long-acting injection in U.S. Takeda’s TYK2 inhibitor zasocitinib tops BMS’ Sotyktu in head-to-head trial for clearing skin in patients with moderate-to-severe plaque psoriasis.</li>
<li>SK Bioscience initiated process development for injectable rotavirus vaccine candidate after entering license agreement with the U.S. CDC. Alteogen’s ALT-B4 received an Intention to Grant decision from European Patent Office.</li>
</ul>


Last week, the U.S. DoD designated Wuxi AppTec as a “Chinese military company.” In response, Wuxi AppTec has filed a complaint at the U.S. District Court.
CSPC Pharmaceutical received trial approval for semaglutide long-acting injection in U.S. Takeda’s TYK2 inhibitor zasocitinib tops BMS’ Sotyktu in head-to-head trial for clearing skin in patients with moderate-to-severe plaque psoriasis.
SK Bioscience initiated process development for injectable rotavirus vaccine candidate after entering license agreement with the U.S. CDC. Alteogen’s ALT-B4 received an Intention to Grant decision from European Patent Office.


APAC Healthcare Weekly (June 14) – Wuxi AppTec, Remegen, CSPC Pharma, Takeda, SK Bioscience Alteogen

<ul>
<li>We analyzed the changes in short interest of Bursa stocks as of Oct 2nd. The aggregated short interest is USD1,438m.</li>
<li>We tabulate league tables for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.</li>
<li>We highlight short interest changes in Nestle (Malaysia), YTL Power International, IJM, Inari Amertron, Frontken.</li>
</ul>


We analyzed the changes in short interest of Bursa stocks as of Oct 2nd. The aggregated short interest is USD1,438m.
We tabulate league tables for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.
We highlight short interest changes in Nestle (Malaysia), YTL Power International, IJM, Inari Amertron, Frontken.


Bursa Short Interest Weekly (Oct 2nd): Nestle (Malaysia), YTL Power International, IJM, Frontken

Malaysia

Top Glove Corporation Bhd manufactures a wide range of latex gloves.  The Company's products include latex examination powdered, latex examination powderfree, nitrile examination gloves,soft nitrile examination gloves, vinyl examination gloves, surgical gloves, and other related products.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Top Glove Corp (TOPG MK)

APAC Healthcare Weekly (Sept 13) – Hansoh, InSilico, Shionogi, Kyowa Kirin, Samsung Bio, SK Biopharm

Hansoh’s risvutatug rezetecan has been included in NMPA’s Priority Review. InSilico initiates rentosertib Phase 3 trial in IPF. Samsung Biologics...

Tina Banerjee

Bursa Short Interest Weekly (Oct 9th): CIMB, Press Metal, Gamuda, AMMB, Pentamaster

We analyzed Bursa Malaysia short interest report for the past week and highlighted short interest changes in CIMB, Press Metal, Gamuda, AMMB,...

Ke Yan, CFA, FRM